Connect with us

International

Djokovic Deported After Losing Visa Appeal, Faces 3-Year Ban From Australia

Djokovic Deported After Losing Visa Appeal, Faces 3-Year Ban From Australia

Authored by Nina Nguyen and Melanie Sun via The Epoch Times,

Novak Djokovic flew out of Australia and is facing a three-year ban from the country after the full…

Published

on

Djokovic Deported After Losing Visa Appeal, Faces 3-Year Ban From Australia

Authored by Nina Nguyen and Melanie Sun via The Epoch Times,

Novak Djokovic flew out of Australia and is facing a three-year ban from the country after the full federal court ruled on Sunday evening to dismiss his challenge to a government decision revoking his visa.

Chief Justice James Allsop said that Djokovic’s application to overturn the Australian immigration minister’s cancellation of his visa had been dismissed unanimously by himself as part of the court’s three-judge panel, alongside Justice Anthony Besanko and Justice David O’Callaghan, after almost eight hours of deliberations on Sunday. All costs are to be paid for by Djokovic.

The Serbian player went to the airport in Melbourne just hours later. Federal agents escorted him and his team from the business lounge to the gate, where he boarded an Emirates flight bound for Dubai. The flight took off shortly before 11 p.m.

Allsop offered to hear further arguments from both parties on the decision, which was given as soon as possible given the wider implications and international attention on the case, as well as Djokovic’s first round Australian Open game against fellow Serb Miomir Kecmanovic that was scheduled for Monday.

However, the world number one tennis player’s legal team declined the invitation.

As a result, he lost his chance to defend his grand slam title at the Australian Open. A draw has decided that Salvatore Caruso will replace the number one seed in the Australian Open first round.

Serbia’s Novak Djokovic holds the Norman Brookes Challenge Cup after defeating Russia’s Daniil Medvedev in the men’s singles final at the Australian Open tennis championship in Melbourne, Australia, on Feb. 21, 2021. (Hamish Blair/AP Photo)

Allsop said that the court’s reasons for its dismissal would be published as soon as possible. He noted that the decision of the Commonwealth judicial branch of government was not about whether a minister from the executive branch of government made the right decision to deny entry to the tennis star, but was about whether Immigration Minister Alex Hawke’s decision was lawful or legal in the context of the three grounds put forward by Djokovic’s appeal.

“These grounds focused on whether the decision was, for different reasons, irrational or legally unreasonable,” Allsop said.

“It is no part of the function of the court to decide upon the merits or wisdom of the [government’s] decision.”

In a statement, Djokovic said that while he respected the ruling, he was “extremely disappointed with the court ruling … which means I cannot stay in Australia and participate in the Australian Open.”

I will now be taking some time to rest and to recuperate, before making any further comments beyond this,” he said, while thanking his team and fans for their support, and asking for their focus to now return to supporting the tournament.

He added that he will be cooperating with the Australian authorities “in relation to my departure from the country.”

Meanwhile, Hawke applauded the court’s upholding his decision to exercise his power under the Migration Act, stressing the importance of Australia’s strong border protection in “safeguarding Australia’s social cohesion.”

“Australia’s strong border protection policies have kept us safe during the pandemic, resulting in one of the lowest death rates, strongest economic recoveries, and highest vaccination rates in the world.

“Australians have made great sacrifices to get to this point and the Morrison Government is firmly committed to protecting this position, as the Australian people expect,” he said in a statement.

The minister added that with Djokovic being viewed as an “icon,” the player’s presence in Australia could excite anti-vaccination sentiment, derail Australia’s vaccination efforts, and ultimately affect the health system.

Djokovic’s lawyers had challenged in court that there was “no evidence” that such a scenario would occur, stressing that Djokovic’s deportation and the government’s “coercive action” would also achieve the same effect.

The immigration minister’s sentiment was echoed by Australian Prime Minister Scott Morrison, who stated that the visa cancellation was “made on health, safety, and good order grounds, on the basis that it was in the public interest to do so.”

“I welcome the decision to keep our borders strong and keep Australians safe,” Morrison said.

Australian tennis player Nick Kyrgios, who previously criticised the Australian government’s “embarrassing” handling of the visa saga, expressed disappointment at the court’s decision on social media.

The world number one’s visa was initially cancelled on Jan. 6 at Melbourne’s international airport hours after Djokovic arrived to participate in the first Grand Slam of 2022 by a border official who said Djokovic did not qualify for a medical exemption.

The federal circuit court later overturned this decision, only for Hawke later to step in and revoke the visa again.

Tyler Durden Sun, 01/16/2022 - 10:32

Read More

Continue Reading

International

UK’s Johnson Urges Talks As Unions Threaten “Biggest Rail Strike In Modern History”

UK’s Johnson Urges Talks As Unions Threaten "Biggest Rail Strike In Modern History"

Authored by Alexander Zhang via The Epoch Times,

British…

Published

on

UK's Johnson Urges Talks As Unions Threaten "Biggest Rail Strike In Modern History"

Authored by Alexander Zhang via The Epoch Times,

British Prime Minister Boris Johnson has urged rail unions to talk to the government before causing “irreparable damage” with strike action.

The National Union of Rail, Maritime, and Transport Workers (RMT) is holding a ballot of its 40,000 members on plans to strike over jobs, pay, and conditions. The ballot is set to close on Tuesday, and the union has claimed that a yes vote could lead to “the biggest rail strike in modern history.”

Another union, the Transport Salaried Staffs’ Association (TSSA), has also warned of a “summer of discontent” with similar action on the way unless pay disputes are resolved.

The prime minister’s official spokesman said on Monday:

“Railways are going through difficult times with passenger numbers down. We need to make sure they’re fit for the future.”

He said the government wants “a fair deal for staff, for passengers, and taxpayers” so that “money isn’t taken away from other essential services” such as the National Health Service.

“The prime minister is firmly of the view that unions should talk to the government before causing irreparable damage to our railways—strikes should be the last resort not the first,” he added.

Transport Secretary Grant Shapps told The Sunday Telegraph that ministers are looking at drawing up laws which would make industrial action illegal unless a certain number of staff are working.

Shapps said the government hopes the unions will “wake up and smell the coffee” and suggested that strikes could put more people off rail travel.

He also accused unions of going straight to industrial action rather than using it as a last resort, adding that railways were already on “financial life support” because of the CCP (Chinese Communist Party) virus pandemic.

Referring to a pledge in the Conservative Party’s 2019 election manifesto, which promised minimum services during rail strikes, he said:

“We had a pledge in there about minimum service levels. If they really got to that point then minimum service levels would be a way to work towards protecting those freight routes and those sorts of things.”

Unions have reacted to the threat with anger.

RMT General Secretary Mick Lynch said, “Any attempt by Grant Shapps to make effective strike action illegal on the railways will be met with the fiercest resistance from RMT and the wider trade union movement.”

He said the government needs to “focus all their efforts on finding a just settlement” to the rail dispute rather than “attack the democratic rights of working people.”

Tyler Durden Tue, 05/24/2022 - 02:00

Read More

Continue Reading

Government

CytoDyn Inc (OTCMKTS: CYDY) On the Comeback Trail (HIV Leronlimab Update)

CytoDyn Inc (OTCMKTS: CYDY) continues to move steadily higher in recent trading since hitting lows of $0.231 after the FDA placed a partial clinical hold…

Published

on

CytoDyn Inc (OTCMKTS: CYDY) continues to move steadily higher in recent trading since hitting lows of $0.231 after the FDA placed a partial clinical hold on the Company’s HIV program and a full clinical hold on its COVID-19 program in the United States. CYDY was one of the biggest runners of 2020 skyrocketing from pennies to $10 per share and MIcrocapdaily covered the stock regularly back in those exciting times. Since than CYDY has been downward bound, first suffering from the Citron short attack and more recently the March 30 drop after the FDA hold. Further, CytoDyn elected to pause its Brazil COVID-19 trials pending results from its previously scheduled data safety monitoring committee meeting and is in the process of reevaluating the timing of its HIV BLA resubmission. CYDY saw further declines after the Company’s CEO and registered public accounting firm, Warren Averett LLC, both resigned. 

On May 23 CYDY reached a non-cash settlement with its former Chief Medical Officer, Dr. Richard Pestell. The Company will release to Dr. Pestell 8.3 million shares of CYDY held in escrow, transfer to Dr. Pestell the assets acquired from ProstaGene LLC and subsequently written-off by the Company and issue a warrant at an exercise price of $0.37 per share to Dr. Pestell for seven million shares of the Company’s common stock. Dr. Pestell and the Company are also exploring ways in which Dr. Pestell can reengage with the Company to help realize Leronlimab’s full potential in oncology. This is an important step forward for CytoDyn as any potential suitor would want the current management to clear the deck of lawsuits before initiating a buyout or partnership. Also, an all-stock settlement shows a lot of faith in the Company from Dr. Pestell who make come back. At this point Cytodyn must find a sponsor or partner to get Leronmilab back on track for HIV. 

The underlying science of Leronmilab has not changed; leronlimab has demonstrated significant potential to attack a number of diseases including cancer, and HIV.  Considering how fast CYDY dropped the bounce potential here is significant and when CYDY does make a definitive move northbound the stock could make rapid gains in a very shorty time period. Management remains hopeful the FDA will review the case and stop the hold of Leronlimab. 

Sign Up now for our 100% FREE Penny Stock Newsletter

CytoDyn Inc (OTCMKTS: CYDY) is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. CytoDyn is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions. 

In January Cytodyn reported positive results from the 350 mg weekly dose of its Phase 2 NASH clinical trial. The trial was conducted in two parts. Part 1 compared a 700 mg weekly dose and placebo in a double-blind randomized manner and Part 2 evaluated a 350 mg weekly dose as an open label study compared to the same placebo blinded arm. Results of the topline report will be announced when available.  

The pre-clinical and clinical development of PRO 140 was led by Progenics Pharmaceuticals, Inc. through 2011. The Company acquired the asset from Progenics in October 2012. In February 2018, CYDY announced it had met the primary endpoint in its Phase 3 trial for leronlimab as a combination therapy with HAART for highly treatment-experienced HIV patients and first submitted the non-clinical portion of the Company’s Biologics License Application (“BLA”) to the FDA in March 2019.  

To Find out the inside Scoop on CYDY Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

CYDY

Cytodyns current business strategy is to resubmit its BLA to the FDA as soon as possible, to finalize with the FDA our submitted protocol for a pivotal Phase 3 clinical trial with leronlimab as a monotherapy for HIV patients, to seek emergency use authorization and approval for leronlimab as a potential therapeutic benefit for COVID-19 patients with mild-to-moderate, severe-to-critical, and long-haulers indications in the U.S., Brazil, and other countries, to advance the Company’s clinical trials with leronlimab for various forms of cancer, including, among others, the Phase 2 clinical trial for metastatic triple-negative breast cancer and Phase 2 basket trial for 22 solid tumor cancers, to complete the Phase 2 trial for liver fibrosis associated with nonalcoholic steatohepatitis (“NASH”), and to explore other cancer and immunologic indications for leronlimab.  

On May 23 CYDY announced it has reached a non-cash settlement with its former Chief Medical Officer, Dr. Richard Pestell, concerning an ongoing legal dispute related to his former employment with the Company. 

Under the terms of the agreement, the parties will release each other of all claims, and the Company will release to Dr. Pestell 8.3 million shares of the Company’s common stock held in escrow, transfer to Dr. Pestell the assets acquired from ProstaGene LLC and subsequently written-off by the Company and issue a warrant at an exercise price of $0.37 per share to Dr. Pestell for seven million shares of the Company’s common stock. Dr. Pestell and the Company are also exploring ways in which Dr. Pestell can reengage with the Company to help realize leronlimab’s full potential in oncology. CytoDyn regrets Dr. Pestell’s departure from the Company and the subsequent public statements made by its former CEO about Dr. Pestell. 

Dr. Pestell has published more than 600 works, is the most frequently cited scientist in the field of cell-cycle control and was appointed an Officer of the Order of Australia in the 2019 Queen’s Birthday Honours for distinguished service to medicine and medical education. He has served on editorial boards of six journals, was the Director of two NCI-designated Cancer Centers and has founded several biotechnology companies. He serves as an advisor and reviewer for a number of domestic and international research centers, including NCI cancer centers. 

For More on CYDY Subscribe Right Now!

Currently trading at a $226 million market valuation CYDY is an SEC filer and is fully reporting OTCQB. The Company has close to $100 million in assets and about that in debt. At current price levels CYDY is worth a close look; CYDY was one of the biggest runners of 2020 skyrocketing from pennies to $10 per share. While there are plenty of ricks not to mention the CEO and accounting firm resigning CYDY is moving northbound now and looks to be coming back. The underlying science has not changed; Leronlimab has demonstrated significant potential to attack a number of diseases including cancer and HIV.  Considering how fast CYDY dropped the bounce potential here is significant and when CYDY does make a definitive move northbound the stock could make rapid gains in a very shorty time period. Management remains hopeful the FDA will review the case and stop the hold of Leronlimab. We will be updating on CYDY when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CYDY.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in CYDY either long or short and we have not been compensated for this article.

The post CytoDyn Inc (OTCMKTS: CYDY) On the Comeback Trail (HIV Leronlimab Update) first appeared on Micro Cap Daily.

Read More

Continue Reading

International

How Inflation Changed The Price Of A Burger

How Inflation Changed The Price Of A Burger

With inflation standing at 8.3% year-over-year in April, everyday items are becoming pricier…

Published

on

How Inflation Changed The Price Of A Burger

With inflation standing at 8.3% year-over-year in April, everyday items are becoming pricier for U.S. consumers. As Statista's Katharina Buchholz details below, food prices in particular took some significant steps up, as seen in the example of shopping for hamburger ingredients.

You will find more infographics at Statista

Meats experienced some of the highest price increases among food items: Ground beef now costs almost 15 percent more than in April 2021 and bacon is 17.7 percent more expensive than one year ago.

On the other hand, the price of tomatoes was up just 0.4 percent over the course of one year, showing that some item suffered less inflation than others.

At a 6.2 percent price increase, fresh vegetables as a whole saw the lowest rate of inflation of any food category.

Energy – the most volatile item in the Consumer Price Index together with foods - drove overall price increases even more. In short supply following the Russian invasion of Ukraine and ensuing sanctions, energy costs rose by 30.3 percent since April 2021. This increase is independent of the base effect as energy prices had already reached pre-pandemic levels again one year ago.

Inflation had already started to rise in 2021 in the aftermath of Covid-19 lockdowns that continue to affect global supply chains. It was further pushed up by the Russian invasion of Ukraine that saw energy supply disrupted by sanctions and Ukrainian products missing from world markets. As a result, inflation is reaching an increasingly broad range of products. For example, while the price of used cars and trucks had already skyrocketed in 2021, new vehicles have now also become 13 percent more expensive than they had been a year ago.

Given the high price of gas and cars, inflation is indirectly encouraging another behavior - using public transportation. The category became 2.7 percent more expensive over the past year.

Tyler Durden Mon, 05/23/2022 - 22:00

Read More

Continue Reading

Trending